Lexicon Pharmaceuticals
Présence
Lexicon Pharmaceuticals fait partie des...
Lexicon Pharmaceuticals est une société cotée sous le symbole boursier LXRX (US).
Dirigeants
Voir l'organigramme avec ses 30 principaux dirigeants
Biographies les plus recherchées chez Lexicon Pharmaceuticals
- Lonnel Coats, President and Chief Executive Officer & Director (r...
- Raymond Debbane, Chairman of the Board
- Philippe Amouyal, Director
Changements de dirigeants chez Lexicon Pharmaceuticals
- Lonnel Coats, President and Chief Executive Officer & Director, partira en retraite le 7 juil. 2024 (publié le 2 mai 2024).
- Lisa Defrancesco rejoindra l'entreprise comme Head of Investor Relations and Corporate Strategy le 13 nov. 2023 (publié le 2 novembre 2023).
- Matthew Cullen, a rejoint l'entreprise comme Vice President of Value and Access (publié le 2 novembre 2023).
Cliquez ici pour voir d'autres changements chez Lexicon Pharmaceuticals
Créer une alerte
pour suivre les mouvements de dirigeants chez Lexicon Pharmaceuticals.
Biotechnologie
Lexicon Pharmaceuticals a 2 285 concurrents dont Lonza (Suisse), Eurofins (Luxembourg) et Adaptive Phage Therapeutics (Etats—Unis).
Actualités en fusion/acquisition en Biotechnologie.
- Karius vient d'annoncer une levée de fonds de 100 millions de dollars. (publié le 3 mai 2024).
- Transcarent vient d'annoncer une levée de fonds de 126 millions de dollars. (publié le 2 mai 2024).
- WindRose Health Investors has announced the acquisition of SubjectWell (publié le 2 mai 2024).
Contacts en Biotechnologie
Actualités
Derniers communiqués de presse par Lexicon Pharmaceuticals
- Lexicon Reveals “into the Dark” Awareness Campaign About Vulnerable and Dangerous Period of Time Faced by Heart Failure Patients Following Hospitalization | Lexicon Pharmaceuticals, Inc.Lexicon Reveals “into the Dark” Awareness Campaign About Vulnerable a
- New Analyses of Sotagliflozin Showing Time to Clinical Benefit Presented at the American College of Cardiology’s 72nd Annual Scientific Session Together with World Heart Federation’s World Congress of Cardiology | Lexicon Pharmaceuticals, Inc.New Analyses
- Lexicon Pharmaceuticals Reports Fourth Quarter 2022 Financial Results and Provides Business Update | Lexicon Pharmaceuticals, Inc.Lexicon Pharmaceuticals Reports Fourth Quarter 2022 Financial Results and Provides Business Update
- Lexicon Pharmaceuticals to Host Fourth Quarter 2022 Financial Results Conference Call and Webcast on March 2, 2023 | Lexicon Pharmaceuticals, Inc.Lexicon Pharmaceuticals to Host Fourth Quarter 2022 Financial Results Conference Call and Webcast on March 2,
- New Analyses of Sotagliflozin to Be Presented at the American College of Cardiology’s 72nd Annual Scientific Session Together with World Heart Federation’s World Congress of Cardiology | Lexicon Pharmaceuticals, Inc.New Analyses of Sotagliflozin to Be Pre
- Lexicon Pharmaceuticals to Participate in the 41st Annual JP Morgan Healthcare Conference | Lexicon Pharmaceuticals, Inc.Lexicon Pharmaceuticals to Participate in the 41st Annual JP Morgan Healthcare Conference
- Lexicon Announces Topline Results from Phase 2 Proof-of-Concept Study of LX9211 in Postherpetic Neuralgia | Lexicon Pharmaceuticals, Inc.Lexicon Announces Topline Results from Phase 2 Proof-of-Concept Study of LX9211 in Postherpetic Neuralgia
- Lexicon Pharmaceuticals to Participate in the 34th Annual Piper Sandler Healthcare Conference and the 5th Annual Evercore ISI HealthCONx Conference | Lexicon Pharmaceuticals, Inc.Lexicon Pharmaceuticals to Participate in the 34th Annual Piper Sandler Heal
- Lexicon’s LX9211 Shows Significant and Consistent Benefits in the Treatment of Painful Diabetic Neuropathy in Full Results from the Phase 2 RELIEF-DPN-1 Trial Presented at the 16th Annual Pain Therapeutics Summit | Lexicon Pharmaceuticals, Inc.Lexicon’s L
- Lexicon Pharmaceuticals to Participate in the 13th Annual Jefferies London Healthcare Conference | Lexicon Pharmaceuticals, Inc.Lexicon Pharmaceuticals to Participate in the 13th Annual Jefferies London Healthcare Conference
- Voir plus de communiqués de presse Close
Réseaux sociaux à propos de Lexicon Pharmaceuticals
- Lexicon Pharmaceuticals sur Wikipédia, Google News & Yahoo Finance en 1-click
- Lexicon Pharmaceuticals sur LinkedIn, Twitter & YouTube en 1-click
Entrer en contact
Contacter par email ses dirigeants dont Lonnel Coats 
Appelez Lexicon Pharmaceuticals au +1 281...
